A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size
Public ClinicalTrials.gov record NCT07881809. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled Trial of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study tests whether a medicine called ixazomib is safe for people living with HIV, and whether it can wake up HIV that is hiding in the body so the immune system and treatment can reach it. HIV can stay hidden inside cells even when antiretroviral therapy (ART) keeps the virus under control. These hidden cells are called the HIV reservoir, and they are the reason HIV is not cured by ART alone. Laboratory research suggests ixazomib may reactivate hidden HIV and also help kill the cells that carry it. Ixazomib is already approved to treat a cancer called multiple myeloma and has been given to a smaller group of people with HIV in an earlier study. About 45 adults with HIV that is well controlled on ART will take part. Participants are assigned by chance to take either ixazomib or a placebo - a capsule with no active medicine - one capsule by mouth once a week for a total of 25 doses. Two out of every three participants receive ixazomib and one out of three receives placebo. Neither participants nor the study staff know which one a participant is taking. Everyone continues their own HIV treatment throughout the study. Participation lasts about 7 months: 24 weeks of weekly capsules and 4 more weeks of follow-up after the last dose. Participants come to the clinic for about 14 visits, and take their capsule 24 to 36 hours before each visit so blood samples can show the effect of the dose. The main purposes of the study are to evaluate whether ixazomib is safe and tolerable, and to measure whether it increases the very small amounts of HIV in the blood compared with placebo. The study also measures the size of the HIV reservoir and how the immune system responds.
Study identification
- NCT ID
- NCT07881809
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 23, 2026 (Estimated)
- Primary completion
- Oct 8, 2027 (Estimated)
- Completion
- Nov 5, 2027 (Estimated)
- Last update posted
- Oct 19, 2026
2026 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS (Site #31788) | Birmingham | Alabama | 35222 | — |
| University of California, Los Angeles CARE Center CRS (Site #601) | Los Angeles | California | 90035 | — |
| UCSD Antiviral Research Center CRS (Site #701) | San Diego | California | 92103 | — |
| University of California, San Francisco HIV/AIDS CRS (Site #801) | San Francisco | California | 94110 | — |
| University of Colorado Hospital CRS (Site #6101) | Aurora | Colorado | 80045 | — |
| Whitman-Walker Institute, Inc. CRS (Site #31791) | Washington D.C. | District of Columbia | 20009 | — |
| The Ponce de Leon Center CRS (Site #5802) | Atlanta | Georgia | 30308-2012 | — |
| Northwestern University CRS (Site #2701) | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital CRS (MGH CRS) (Site #101) | Boston | Massachusetts | 02114 | — |
| Columbia Physicians & Surgeons (P&S) CRS (Site #30329) | New York | New York | 10032 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site #31787) | Rochester | New York | 14642 | — |
| Chapel Hill CRS (Site #3201) | Chapel Hill | North Carolina | 27599-7215 | — |
| Cincinnati Clinical Research Site (Site #2401) | Cincinnati | Ohio | 45267-0405 | — |
| Case Clinical Research Site (Site #2501) | Cleveland | Ohio | 44106 | — |
| Ohio State University CRS (Site #2301) | Columbus | Ohio | 43210-1282 | — |
| Penn Therapeutics CRS (Site #6201) | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS (Site #1001) | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) CRS (Site #3652) | Nashville | Tennessee | 37204 | — |
| Houston Advancing Research Team CRS (Site #31473) | Houston | Texas | 77030 | — |
| University of Washington Positive Research CRS (Site #1401) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07881809, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07881809 live on ClinicalTrials.gov.